title: A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.
abstract: Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. Its feasibility, however, is limited by the requirement for a patient-specific product. Here we describe a novel vaccine formulation prepared by simply extracting cell-membrane proteins from lymphoma cells and incorporating them together with IL-2 into proteoliposomes. The vaccine was produced in 24 hours, compared with more labor-intensive and time-consuming hybridoma or recombinant DNA methods. The vaccine elicited T-cell immunity in vivo, as demonstrated by secretion of type 1 cytokines. It protected against tumor challenge at doses of tumor antigen 50 to 100 times lower than that previously observed using either liposomes formulated with IL-2 and secreted lymphoma immunoglobulin or a prototype vaccine consisting of lymphoma immunoglobulin conjugated to keyhole limpet hemocyanin. The increased potency justifies testing similar patient-specific human vaccines prepared using extracts from primary tumor samples.
authors.affiliation: XEME Biopharma, Plainsboro, NJ 08536, USA. mpopescu@xemebiopharma.com
authors.forename: Mircea C
authors.initials: MC
authors.lastname: Popescu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Robb
authors.forename: Michael M
authors.initials: MM
authors.lastname: Batenjany
authors.forename: Lawrence T
authors.initials: LT
authors.lastname: Boni
authors.forename: Mary E
authors.initials: ME
authors.lastname: Neville
authors.forename: Robin W
authors.initials: RW
authors.lastname: Pennington
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines / Q000276:immunology* / Q000494:pharmacology; D005260:Female; D007109:Immunity; D016393:Lymphoma, B-Cell / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011510:Proteolipids / Q000627:therapeutic use*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D011510:Proteolipids; C020485:proteoliposomes